TaiLai Biosciences
Latest round
- Series A
Last raised
- Dec 2020
Total raised
- $15M
Investors
- 3
About TaiLai Biosciences
Based in Shenzhen, China and established in 2018, TaiLai Biosciences is a biotech company engaged in the development of innovative liquid biopsy products and services for early cancer screening and diagnosis. TaiLai Biosciences' CEO, Stanley Lau, brings 40 years of experience in the pharmaceutical and healthcare industry, having held senior positions in multinational corporations such as Merck, Schering-Plough, and Baxter. The team consists of professionals with expertise in various omics fields, collaborating with top hospitals and international immunotherapy companies for research and development. TaiLai Biosciences focuses on the research and development of cancer screening technologies. Their flagship product, Meta-Pan® (An'an Pan®), offers early risk warning for 14 common types of cancer in China. The company's products are designed to provide comprehensive and reliable cancer screening services, with applications in healthcare institutions, insurance organizations, and for individual consumers. The company generates revenue by providing cancer screening services and diagnostic products to a wide range of clients, including medical institutions and individual consumers.
Who invested in TaiLai Biosciences
3 investors across 1 round
See all investors in TaiLai Biosciences
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
Dec 30, 2020
Amount
$15M
Investors
Questions about TaiLai Biosciences
Who invested in TaiLai Biosciences?
TaiLai Biosciences has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has TaiLai Biosciences raised?
TaiLai Biosciences has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did TaiLai Biosciences last raise money?
TaiLai Biosciences's most recent round on record is a Series A, in Dec 2020.
What does TaiLai Biosciences do?
Based in Shenzhen, China and established in 2018, TaiLai Biosciences is a biotech company engaged in the development of innovative liquid biopsy products and services for early cancer screening and diagnosis.
Where is TaiLai Biosciences headquartered?
TaiLai Biosciences is headquartered in Shenzhen, China.
Which VCs invest in companies like TaiLai Biosciences?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back healthcare specialists companies at TaiLai Biosciences's stage. Their profiles are linked below.
VCs backing healthcare specialists startups at Series A
Raising like TaiLai Biosciences? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.